Alzheimer's Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense
Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from Medicare.
Full Article
Alzheimer's Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense
Upworthy
0 shares
2 views
You might like
Related news coverage
Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense
Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from..
NYTimes.com